Inyx Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Date: May 15, 2018
Pages: 50
US$ 499.00
Inyx Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Publisher: BAC Reports
Report type: Strategic Report
Delivery: E-mail Delivery - PDF (on default),
Hard Copy Mail Delivery (+US$ 190.00)
ID: I405F31E94BBEN

Download PDF Leaflet

Inyx Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Inyx Inc. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Inyx Inc. and its competitors. This provides our Clients with a clear understanding of Inyx Inc. position in the Pharmaceuticals and Biotechnology Industry.

  • The report contains detailed information about Inyx Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
  • Another part of the report is a SWOT-analysis carried out for Inyx Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
  • The Inyx Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
  • In the part that describes Inyx Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
  • Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Inyx Inc. business.

About Inyx Inc.

Inyx, Inc., through its wholly-owned subsidiaries, engages in the development and manufacture of prescription and over-the-counter aerosol pharmaceutical products. It also provides specialty pharmaceutical development and manufacturing consulting services to the international healthcare market.

On March 31, 2005, the company acquired the business assets of Aventis PR from the Sanofi-Aventis Group. In August 2005, through its wholly-owned United Kingdom subsidiary, Inyx Europe, the company completed the purchase of Celltech Manufacturing Services Limited (CMSL), a United Kingdom pharmaceutical manufacturing company, from UCB Pharma Limited. In September 2005, the company changed the CMSL name to Ashton Pharmaceuticals Limited.


The company's wholly owned subsidiaries include Inyx USA, Ltd. (Inyx USA), Inyx Pharma Limited (Inyx Pharma), Inyx Canada Inc. (Inyx Canada), Inyx Europe Limited (Inyx Europe). Inyx Europe’s wholly-owned subsidiaries include Ashton Pharmaceuticals Limited (Ashton Pharmaceuticals or Ashton) and Exaeris Inc. (Exaeris).

Metered Dose Inhalers (MDIs)

The Company develops and manufactures metered dose inhalers (MDIs), used primarily for respiratory conditions, which employ both chlorofluorocarbon (CFC) and hydrofluroalkane (HFA) propellant technologies. CFC-based products include Salbutamol, a mild asthma and rescue therapy, and Beclomethasone, a steroid used as an anti-inflammatory for respiratory disease. HFA products include MDIs for respiratory ailments and a metered dose oral (MDO) spray, such as a GTN spray which is a nitrate propelled HFA aerosol that is used for prescription and over the counter products, primarily for cardiac ailments.

Dry Powdered Inhalers (DPIs)

The Company assists in the development and production of dry powder inhalers (DPIs), which are primarily used for respiratory ailments, such as asthma. Specific products in this area include Salbutamol, and Beclomethasone. It is also reviewing the use of Budesonide, an anti-inflammatory corticosteroid, and Formeterol, a bronchodilator, as DPIs. Its major customer in the DPI area has licensed the DPI device (the Clickhaler) that the Company manufactures under a license agreement from a UK-based biotechnology company.

Metered Dose Pump Sprays (MDPSs)

The Company develops and produces metered dose nasal and throat pumps and sprays (MDPSs) for nasal decongestion, anti-allergic and anti-inflammatory applications. Products within these areas include corticosteroid products, such as a Beclomethasone Dipropionate for the treatment of allergy conditions.

Hydrocarbon Aerosols

The Company develops and manufactures hydrocarbon aerosols as a delivery system for dermatological and topical drug applications. It utilizes two hydrocarbon aerosol filling lines. These manufacturing lines are equipped with fire suppressant equipment, protected gassing of hydrocarbons, remote monitoring equipment, and manufacturing areas.

Dermatological Creams, Lotions and Ointments

The Company develops and manufactures creams, lotions and ointments for dermatological and topical drug applications. The drug is a corticosteroid or similar anti-inflammatory agent formulated with excipients and is manufactured in depending on the potency required.

Saline Aerosols & Injectables

The Company develops and manufactures products that are nitrogen propelled buffered and non-buffered normal aerosols for eye and wound care. These include the water-for-injection/alcohol aerosols and non-alcohol based disinfectant aerosols. It also offers various fully and semi-automated packaging lines for a range of presentations.

Solid Dose (Tablets and Capsules)

Ashton also has expanded the company's development and production capabilities into solid dose, including sustained-release capsules. At Ashton, the company has computer controlled compression machines capable of producing up to 200,000 tablets per hour. It also has film tablet coating areas that process aqueous and solvent formulations as well as sugar coating.


The Company's major suppliers include Cebal U.K. Limited; Valois U.K., Ltd; LABLABO; Bespak Europe, Ltd; 3M; Precision Valve (U.K.), Ltd.; Nussbaum (U.K.), Ltd.; Eurand SpA; and Innovata Biomed plc.


The Company's major customers include Kos Pharmaceuticals, Inc.; UCB Pharma Ltd.; and Sanofi-Aventis Group.


Inyx, Inc. was incorporated in 2000 under the name Doblique, Inc. and changed its name to Inyx, Inc. in 2003.

The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.




1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History


2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units


3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats


4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot


5.1. Inyx Inc. Direct Competitors
5.2. Comparison of Inyx Inc. and Direct Competitors Financial Ratios
5.3. Comparison of Inyx Inc. and Direct Competitors Stock Charts
5.4. Inyx Inc. Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Inyx Inc. Industry Position Analysis


6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events


7.1. Experts Opinion
7.2. Experts Estimates



9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors


10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix





Inyx Inc. Key Facts
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Inyx Inc. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Inyx Inc. Major Shareholders
Inyx Inc. History
Inyx Inc. Products
Revenues by Segment
Revenues by Region
Inyx Inc. Offices and Representations
Inyx Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Inyx Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Inyx Inc. Capital Market Snapshot
Inyx Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Inyx Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Inyx Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Historical Surprises1
Revenue Estimates Trend1
Earnings Estimates Trend1
Revenue Revisions1


Inyx Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Inyx Inc. 1-year Stock Charts
Inyx Inc. 5-year Stock Charts
Inyx Inc. vs. Main Indexes 1-year Stock Chart
Inyx Inc. vs. Direct Competitors 1-year Stock Charts
Inyx Inc. Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

  • How to use the strengths to take advantage of the opportunities?
  • How to use the strengths to reduce likelihood and impact of the threats?
  • How to overcome the weaknesses that obstruct taking advantage of the opportunities?
  • How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

  • Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
  • Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
  • Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
  • Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
  • Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
  • Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.

Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

  1. What composes a threat of substitute products and services?
  2. Is there a threat of new competitors entering the market?
  3. What is the intensity of competitive rivalry?
  4. How big is the bargaining power of buyers?
  5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

  • Tangible resources
    • Financial
    • Physical
    • Technological
    • Organizational
  • Intangible resources
    • Human
    • Innovation and Creativity
    • Reputation
  • Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

  • Valuable?
  • Rare?
  • Costly to imitate?
  • Organized properly?
Skip to top

Ask Your Question

Inyx Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: